SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Immunomedics (IMMU) - moderated
An SI Board Since September 2006
Posts SubjectMarks Bans Symbol
63310 355 15 IMMU
Emcee:  idahoranch1 Type:  Moderated
Welcome to the troll-free, moderated message board, made up of primarily ex-IMMU shareholders.
- IMMU's status:
--It is now a fully owned subsidiary of Gilead.

This board of ex IMMU shareholders who have gained the respect and trust of each other over many frustrating years of disappointment and heartache, yet having a thrilling ending, who still like to check in on what each other is thinking about other biotech investments. On the downside, the IMMU buyout was one of the last positive events in biotech before falling out of favor as a sector, and the efforts to turn some of the cash from the buyout into more growth has been a rough patch. However, most of us have gone through very rough and long periods of frustration and so most are experienced and seem to be mentally weathering this rough patch rather well.

Hopefully the combined knowledge and wisdom on this board will be financially beneficial over time in the biotech sector. I continue to monitor the board to keep it at the highest level that it has attained.

Etiquette:

This board is moderated, meaning the moderator (me) can stop people from posting here if they violate our norms. What are "our norms"? Well, be adult, play nice about sums it up. There are three responses I encourage for keeping the discussion civil and useful when you encounter a post that annoys you. In order of preference:

1> report a ToU violation to the SI admins via the link at the bottom of each post, they're good at dealing with problems.

2> send the person who posted a private message and work it out. Privately.

3> send me a private message. Wait a couple of days before doing so please, I'll usually see the message in that time frame and act (or not).

4> stay focused and leave politics out of it, even by inference. There are numerous forums you can spend as much time expounding on your favorite "why (insert favorite hot-button) is evil", we don't need to reiterate all that here.

5> do not engage in discussions about poster's motivations, etc. First of all, it's unprovable. Second I'd rather not wade through the inevitable pointless back-and-forth over something that'll never be settled anyway.

This board provides a forum for honest, civilized and friendly conversation. It is not a vehicle for spam or hidden agendas. New posters are not only welcome but are an important way to bring additional information and insights to the board. Over the years new posters have been welcomed into the group and have helped make the board successful. However, if you’re a new poster it is especially important to be sure that material assertions, be they pro or con, are thoughtful and supportable. While all posters must abide by the TOU, leeway can and will be granted to long-time posters who have made substantive contributions to the board and whose credibility has been established.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
63310NLST: I just tripled down at $.80, market cap: $247M. There is finally some lighghettogoulash-yesterday
63309I also deeply distrust the current AI hype. This totally feels like the dot.com erickerickson1yesterday
63308It is disgusting how much capital is being dumped into a technology that is not ghettogoulash-Thursday
63307IMNM webcast from this morning ... sounds very positive here is link to webcasplhky3465-December 3
63306paypal.comsysiphus1December 2
63305PYPL , imo, is a logical acquisition for TESLA and is very undervalued right nowgalt-December 2
63304I have no specific AI names to suggest but do have some general thoughts about hOlecranon1December 1
63303OT Seems like small biotechs are facing significant headwinds from Washington wsysiphus-November 30
63302AUPH - Nice to end the week at $16.37 Weird that the spread is $4.75 between Bidorightbythem-November 26
63301SRPT Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhancederickerickson2November 25
63300GLUE: The Novartis deal was announced something like 2 months ago, which producerickerickson-November 25
63299Maybe: In its Q3 2025 report, Monte Rosa announced a major new collaboration witsysiphus2November 24
63298Guess that got something "unstuck" :)Davidoff1November 24
63297GLUE: My poetry contribution for today: Anyone got a clue What is up with GLUEerickerickson-November 24
63296IBRX NewsNation is airing an hour-long spplhky3465-November 24
63295Yeah, saw that. Seems like we've been here before with some other company...erickerickson1November 18
63294Erick, fwiw ORGN is seeking approval of a floorless convertible. The $.62 converghettogoulash1November 17
63293My friends at Wells Fargo were bigger supporters. it's cost me But they fouEMU2-November 12
63292Anavex (AVXL) had a preauthorization oral explanation meeting with the FDA yesteOlecranon1November 12
63291re: GLUE up 14% after a poster presentation? Poster presentation Saturday All erickerickson1November 10
63290Finally out of Auph with a nice profit. Had to average down a number of times bgalt-November 9
63289AUPH is gaining on SRPT, who would have thought.idahoranch12November 7
63288Gilead fails late-stage trial for Trodelvy in first-line breast cancerDavidoff-November 7
63287Expert witness hahaha. These Federal F*cks just copy and pasted everything Heilbghettogoulash1November 7
63286Just saw this. The U.S. Department of Justice dismissed with prejudice all chargghettogoulash2November 7
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):